M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Phase 2

Active, not recruiting

Conditions: Ovarian Cancer
Endometrial Cancer

Interventions: Drug: Copanlisib
Drug: fulvestrant

First Posted Date: 2021-10-18

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT05082025

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Esophageal
Gastric Cancer
Metastatic Head and Neck Carcinoma
Metastatic Hepatocellular Carcinoma
Metastatic HPV Related Solid Tumors
Metastatic Soft Tissue Sarcoma
Metastatic Ovarian Carcinoma
Metastatic Uveal Melanoma

Interventions: Drug: LVGN3616 + LVGN6051 + Nab-Paclitaxel
Drug: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide
Drug: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
Drug: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide

First Posted Date: 2021-10-13

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 352

Registration Number: NCT05075993

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Interdisciplinary Interventions to Address Pain Management Among Head and Neck Cancer Patients

Phase 2

Recruiting

Conditions: Head and Neck Carcinoma

Interventions: Other: Best Practice
Other: Counseling
Procedure: Electroencephalography
Other: Questionnaire Administration
Behavioral: Neurofeedback

First Posted Date: 2021-10-13

Last Posted Date: 2024-10-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 72

Registration Number: NCT05077072

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer

Completed

Conditions: Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Prognostic Stage III Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Invasive Breast Carcinoma
Prognostic Stage IIIB Breast Cancer AJCC v8

Interventions: Procedure: Discussion
Other: Interview
Other: Survey Administration

First Posted Date: 2021-10-08

Last Posted Date: 2023-08-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT05071677

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

Phase 2

Active, not recruiting

Conditions: Carcinomas
Cervix Cancer
Cervical Cancer

Interventions: Drug: AK104

First Posted Date: 2021-10-01

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT05063916

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Phase 2

Recruiting

Conditions: Tumor
Brain Metastases

Interventions: Drug: Pembrolizumab
Drug: Lenvatinib

First Posted Date: 2021-10-01

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 104

Registration Number: NCT05064280

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin

First Posted Date: 2021-10-01

Last Posted Date: 2024-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05065047

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

CtDNA-Directed Post-Hepatectomy Chemotherapy for Patients with Resectable Colorectal Liver Metastases

Phase 2

Recruiting

Conditions: Liver Metastases

Interventions: Drug: Leucovorin
Drug: Capecitabine
Drug: 5-FLUOROURACIL
Drug: Oxaliplatin
Drug: Irinotecan
Drug: Bevacizumab

First Posted Date: 2021-09-30

Last Posted Date: 2024-11-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT05062317

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Positron Emission Tomography for the Diagnosis of Immune Checkpoint Inhibitor-Related Myocarditis

Completed

Conditions: Myocarditis Acute

Interventions: Procedure: Computed Tomography
Other: Fludeoxyglucose F-18
Other: Low Carbohydrate High Fat Diet
Procedure: Positron Emission Tomography

First Posted Date: 2021-09-30

Last Posted Date: 2023-04-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT05062395

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Use of Google Translate to Enhance Patient Pain and Nausea Assessment and Satisfaction After General Anesthesia

Completed

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Other: Medical Device Usage and Evaluation
Other: Survey Administration

First Posted Date: 2021-09-29

Last Posted Date: 2022-04-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT05060328

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy